Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer

TOP - November 2017, Vol 10, No 4 - Prostate Cancer

Chicago, IL—The results from 2 studies should advance the use of abiraterone acetate (Zytiga) to the frontline treatment of patients with hormone-sensitive advanced prostate cancer, effectively replacing chemotherapy, said several experts at the 2017 ASCO annual meeting.

Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.

In the LATITUDE study, men with high-risk metastatic prostate cancer who received abiraterone plus ADT and prednisolone had a 38% reduction in mortality risk, with a median follow-up of 2 to 2.5 years, compared with ADT plus placebo.

“Several years ago, the STAMPEDE trial actually showed benefit associated with chemotherapy added to conventional hormone therapy for metastatic prostate cancer. Here, the same study backbone is used to show the benefit of abiraterone,” said ASCO expert Sumanta K. Pal, MD, Co-Director, Kidney Cancer Program, City of Hope, Duarte, CA. “Abiraterone should change the treatment paradigm for patients with newly diagnosed metastatic prostate cancer and largely displaces chemotherapy from the current paradigm.”


In the STAMPEDE study, 1917 men with high-risk prostate cancer were randomized to ADT plus abir­aterone 1000 mg daily and prednisolone 5 mg daily, or the standard of care with ADT and radiation therapy. Standard therapy involved ADT for ≥2 years; radiation therapy was also mandated for men with node-negative, nonmetastatic disease and encouraged for those with node-positive, nonmetastatic disease.

The 3-year overall survival (OS) rate was 76% in men who received standard therapy compared with 83% in men who received standard therapy plus abir­aterone and prednisolone (hazard ratio, 0.63; P = .0012).

“Our projections are that in the experimental arm, in the metastatic part of the comparison, the median survival will be around 3.5 years in our population to 6.5 years for the abiraterone [arm], so we think this is one of the biggest survival gains ever reported in a trial of an adult solid tumor,” said lead investigator Nicholas D. James, PhD, BSc, MBBS, FRCP, FRCR, Professor of Clinical Oncology, Queen Elizabeth Hospital Birmingham, United Kingdom.

The effect on OS of adding abir­aterone and prednisolone to standard therapy was similar in men with metastatic or nonmetastatic disease. “We think these survival data apply to the whole trial population, not just to the metastatic subpopulation,” said Dr James.

The rates of failure-free survival at 3 years were 75% with abiraterone plus prednisolone and standard therapy versus 45% with standard therapy, corresponding to a 71% relative improvement in risk with abiraterone. The relative risk for skeletal-related outcomes was also reduced by 55% in the abiraterone group.

These findings should prompt a change in the upfront care of patients with newly diagnosed advanced prostate cancer to include abiraterone, said Dr James.


In the LATITUDE clinical trial, 1199 men with newly diagnosed, high-risk, metastatic prostate cancer who had not previously received ADT were randomized to receive ADT plus abir­aterone and prednisolone or ADT plus placebo. At a median follow-up of 30.4 months, the median OS had not yet been reached in the abiraterone group versus 34.7 months in the placebo group, for a 38% reduction in the risk for death, favoring abiraterone (P <.0001), reported Karim Fizazi, MD, PhD, Head, Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

Abiraterone plus prednisolone and ADT was also associated with a 53% reduction in the risk for radiographic progression-free survival compared with ADT plus placebo (33.0 months vs 14.8 months, respectively; P <.0001).

“These important findings will very likely change the standard of care of patients who have evidence of metastatic disease at the time of prostate cancer diagnosis,” said Dr Fizazi.

Adverse events with abiraterone therapy in both clinical trials were predominantly cardiovascular-related, including hypertension, which was approximately twice as common in the abiraterone groups than in the control groups. Liver enzyme abnormalities were also more common in the abir­aterone groups than in the control groups.

Related Items
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Genetic Score Makes PSA Screening More Accurate
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Prostate Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Prostate Cancer
NCCN Risk Classification Suboptimal for Some African-American Men with Prostate Cancer
Charlie Dawson
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Prostate Cancer
Targeted Radiotherapy Prolongs Survival in Patients with Advanced Prostate Cancer
Charlie Dawson
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Prostate Cancer
Relugolix May Become New Standard of Care for Advanced Prostate Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in Prostate Cancer
Immune Checkpoint Inhibitor Does Not Improve Outcomes in Metastatic Prostate Cancer
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Prostate Cancer
Androgen-Deprivation Therapy Seldom Used with Radiation in Localized Prostate Cancer
Wayne Kuznar
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Prostate Cancer
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Web Exclusives published on May 26, 2020 in FDA Updates, Prostate Cancer
Last modified: July 22, 2021